Ozempic for Addiction? The Science Is Catching Up to the Headlines

What the Evidence Actually Shows

GLP-1 receptor agonists — the drug class behind Ozempic, Wegovy, and Mounjaro — are generating serious addiction medicine interest well beyond the weight loss headlines. The mechanism is plausible: these drugs modulate the brain’s dopamine reward pathways, reducing the intensity of craving signals that drive compulsive use.

A 2024 study in Nature Communications found that people prescribed semaglutide had a 50–56% lower risk of developing or relapsing into alcohol use disorder compared with people on other anti-obesity medications. A large Veterans Administration study published in March 2026 confirmed the association across multiple substance classes — alcohol, nicotine, cannabis, opioids, and cocaine — and found GLP-1 use was associated with reductions in life-threatening events including drug-related overdoses and deaths.

The preclinical picture has been consistent: GLP-1 agonists reduce self-administration of methamphetamine, cocaine, and alcohol in animal models, attenuate drug-seeking behavior, and blunt relapse-like patterns after a period of abstinence.

What’s Still Missing

The FDA has not approved any GLP-1 drug for addiction treatment. The Veterans studies are observational — they show association, not causation. Randomized controlled trial data is still catching up.

The VA has launched a Phase 3 trial testing semaglutide specifically for alcohol use disorder reduction. Eli Lilly is running trials on brenipatide, an experimental compound targeting alcohol, tobacco, and opioid use disorders simultaneously. Results expected 2027–2028.

Why This Matters for People in Recovery

If GLP-1 drugs prove effective at clinical trial scale, they would represent a category-defining expansion of addiction medicine’s pharmacological toolkit. For the 85% of Americans with SUD who currently receive no treatment, a well-tolerated medication that reduces craving without requiring abstinence as a prerequisite could meaningfully lower the barrier to engagement.